company background image
SUVEN logo

Suven Life Sciences NSEI:SUVEN Stock Report

Last Price

₹131.87

Market Cap

₹28.7b

7D

15.6%

1Y

12.3%

Updated

05 Feb, 2025

Data

Company Financials

Suven Life Sciences Limited

NSEI:SUVEN Stock Report

Market Cap: ₹28.7b

SUVEN Stock Overview

A clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. More details

SUVEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (₹76M)

Earnings have declined by 14.6% per year over past 5 years

Volatile share price over the past 3 months compared to the Indian market


My Notes

Capture your thoughts, links and company narrative

Suven Life Sciences Limited Competitors

Tarsons Products

NSEI:TARSONS

₹20.0b

Dishman Carbogen Amcis

NSEI:DCAL

₹38.3b

Vimta Labs

BSE:524394

₹20.7b

Borosil Scientific

BSE:544184

₹14.3b

Price History & Performance

Summary of share price highs, lows and changes for Suven Life Sciences
Historical stock prices
Current Share Price₹131.87
52 Week High₹169.30
52 Week Low₹82.95
Beta1.43
1 Month Change7.68%
3 Month Change0.76%
1 Year Change12.28%
3 Year Change51.49%
5 Year Change225.60%
Change since IPO-62.11%

Recent News & Updates

Recent updates

Suven Life Sciences (NSE:SUVEN) Is In A Good Position To Deliver On Growth Plans

Oct 26
Suven Life Sciences (NSE:SUVEN) Is In A Good Position To Deliver On Growth Plans

Companies Like Suven Life Sciences (NSE:SUVEN) Are In A Position To Invest In Growth

Jun 21
Companies Like Suven Life Sciences (NSE:SUVEN) Are In A Position To Invest In Growth

How Much Did Suven Life Sciences'(NSE:SUVEN) Shareholders Earn From Share Price Movements Over The Last Year?

Aug 26
How Much Did Suven Life Sciences'(NSE:SUVEN) Shareholders Earn From Share Price Movements Over The Last Year?

Shareholder Returns

SUVENIN Life SciencesIN Market
7D15.6%5.3%2.4%
1Y12.3%47.5%5.8%

Return vs Industry: SUVEN underperformed the Indian Life Sciences industry which returned 46.3% over the past year.

Return vs Market: SUVEN exceeded the Indian Market which returned 5.9% over the past year.

Price Volatility

Is SUVEN's price volatile compared to industry and market?
SUVEN volatility
SUVEN Average Weekly Movement8.0%
Life Sciences Industry Average Movement6.6%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.3%

Stable Share Price: SUVEN's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: SUVEN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
1989141Venkat Jastiwww.suven.com

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders.

Suven Life Sciences Limited Fundamentals Summary

How do Suven Life Sciences's earnings and revenue compare to its market cap?
SUVEN fundamental statistics
Market cap₹28.74b
Earnings (TTM)-₹1.43b
Revenue (TTM)₹75.74m

379.5x

P/S Ratio

-20.1x

P/E Ratio

Is SUVEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SUVEN income statement (TTM)
Revenue₹75.74m
Cost of Revenue₹8.24m
Gross Profit₹67.50m
Other Expenses₹1.50b
Earnings-₹1.43b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-6.57
Gross Margin89.12%
Net Profit Margin-1,892.54%
Debt/Equity Ratio0.1%

How did SUVEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 06:05
End of Day Share Price 2025/02/05 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Suven Life Sciences Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
null nullDBS Bank Ltd
null nullDolat Capital Market Pvt. Ltd.